Compare · NVS vs YARW
NVS vs YARW
Side-by-side comparison of Novartis AG (NVS) and Yarrow Bioscience Inc. (YARW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and YARW operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $305.69B, about 1440.4x YARW ($212.2M).
- Over the past year, NVS is up 21.8% and YARW is down 23.3% - NVS leads by 45.1 points.
- YARW has been more active in the news (13 items in the past 4 weeks vs 5 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 2 for YARW).
- Company
- Novartis AG
- Yarrow Bioscience Inc.
- Price
- -
- -
- Market cap
- $305.69B
- $212.2M
- 1M return
- +6.36%
- -29.07%
- 1Y return
- +21.79%
- -23.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 5
- 13
- Recent ratings
- 25
- 2
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Yarrow Bioscience Inc.
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potential first-in-class anti-thyroid stimulating hormone receptor monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease and thyroid eye disease.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
Latest YARW
- Amendment: SEC Form SCHEDULE 13G/A filed by Yarrow Bioscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Yarrow Bioscience Inc.
- SEC Form SCHEDULE 13G filed by Yarrow Bioscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Yarrow Bioscience Inc.
- Jefferies initiated coverage on Yarrow Bioscience with a new price target
- SEC Form S-8 filed by Yarrow Bioscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Yarrow Bioscience Inc.
- SEC Form SCHEDULE 13G filed by Yarrow Bioscience Inc.
- SEC Form 10-Q filed by Yarrow Bioscience Inc.
- Yarrow Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits